Surface Enhanced Biocompatible Blood Oxygenators

表面增强型生物相容性血液氧合器

• 批准号: 7997627
• 负责人: Daniel Campos
• 金额: $ 12.71万
• 依托单位: COMPACT MEMBRANE SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-01 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7997627
• 关键词: Adult Respiratory Distress Syndrome; Area; Biocompatible; Blood; Bypass; Cardiopulmonary; Chemistry; Development; Devices; Dialysis procedure; Elements; Extracorporeal Membrane Oxygenation; Family; Gases; Hemodialysis; Heparin; Membrane; Operative Surgical Procedures; Oxygen; Polyethylene Glycols; Polypropylenes; Postoperative Period; Proteins; Resistance; Surface; System; Techniques; Technology; Trillium; Variant; Work; artificial lung; base; biomaterial compatibility; blood oxygenator; monomer; novel; polymerization; programs; public health relevance; success

DESCRIPTION (provided by applicant): Compact Membrane Systems, Inc. proposes to develop novel blood oxygenator membranes with enhanced blood biocompatibility. These will be used to enhance conventional cardio bypass surgery minimizing post operative effects. In addition, they will provide a key element for long term blood oxygenation associated with extracorporeal membrane oxygenation, acute respiratory distress syndrome, and artificial lungs. Membrane based blood oxygenators are successfully used for cardiopulmonary by-pass surgery. A number of programs are evaluating long-term membrane based blood oxygenators for artificial lungs and acute respiratory distress syndrome. For both short-term use and long-term use, there is a need for enhanced blood compatible surfaces. Examples of two coating systems that are presently used to enhance blood compatibility are Avecor's Trillium and Medtronic's Carmeda. While both of these systems have some success in enhancing blood compatibility, the success is limited. These systems tend to reduce gas (oxygen) flux and most importantly are prone to wetting out. Materials and devices that contact blood, such as blood tubing, dialysis membranes and blood oxygenators, require blood compatibility of the component materials. This includes consideration of the protein and cellular systems of the blood. Proper control of surface chemistry can enhance biocompatibility. Compact Membrane Systems, Inc. (CMS) has significant expertise in this area. A family of non-porous membranes with excellent gas transport that allows the use of a non-porous membrane to provide the needed wet out resistance for long term blood oxygenation while maintaining high gas transport has been developed by CMS. These membranes will now be used as the building block for enhancing biocompatibility. The net result will be a blood oxygenation membrane with the following features: gas flux comparable to micro porous polypropylene; wet out resistance of a non-porous membrane; and, excellent blood biocompatibility. This work will focus on enhancing the biocompatibility of blood oxygenators by controlling surface chemistry. The technology developed should allow similar developments on hemodialysis membranes and also working with polymerization of heparin to the surface of membranes. PUBLIC HEALTH RELEVANCE: Compact Membrane Systems, Inc. proposes to develop novel blood oxygenator membranes with enhanced blood biocompatibility. These will be used to enhance conventional cardio bypass surgery minimizing post operative effects. In addition, they will provide a key element for long term blood oxygenation associated with extracorporeal membrane oxygenation, acute respiratory distress syndrome, and artificial lungs.

描述(由申请人提供)：紧凑型膜系统公司计划开发具有增强血液生物相容性的新型血液氧合器膜。这些将被用来加强传统的心脏搭桥手术，将术后影响降至最低。此外，它们还将为与体外膜氧合、急性呼吸窘迫综合征和人工肺相关的长期血液氧合提供关键因素。膜式血氧机已成功应用于体外循环手术。许多项目正在评估长期使用基于膜的血液氧合器治疗人工肺和急性呼吸窘迫综合征。无论是短期使用还是长期使用，都需要增强血液相容性表面。目前用于增强血液相容性的两种涂层系统的例子是Aveor的Trillium和美敦力的Carmeda。虽然这两个系统在提高血液相容性方面都取得了一些成功，但成功是有限的。这些系统往往会减少气体(氧气)的流量，最重要的是容易被湿透。与血液接触的材料和设备，如血管、透析膜和血液氧合器，需要组成材料的血液相容性。这包括对血液的蛋白质和细胞系统的考虑。适当的表面化学控制可以提高生物相容性。紧凑型膜系统公司(CMS)在这一领域拥有丰富的专业知识。CMS开发了一系列具有良好气体传输性能的无孔膜，允许使用非多孔膜在保持高气体传输的同时提供长期血液氧合所需的湿出阻力。这些膜现在将被用作增强生物相容性的基础。最终的结果将是一种具有以下特征的血液氧合膜：气体通量与微孔聚丙烯相当；无孔膜的耐湿性；以及优异的血液生物相容性。这项工作将集中在通过控制表面化学来提高血液氧合器的生物相容性。开发的技术应该可以在血液透析膜上进行类似的开发，也可以用于肝素在膜表面的聚合。 与公共健康相关：紧凑型膜系统公司建议开发具有增强血液生物相容性的新型血液氧合器膜。这些将被用来加强传统的心脏搭桥手术，将术后影响降至最低。此外，它们还将为与体外膜氧合、急性呼吸窘迫综合征和人工肺相关的长期血液氧合提供关键因素。